Role of taxanes in adjuvant chemotherapy for breast cancer

Bolotina L.V.; Koroleva L.A.; Deshkina T.I.

doi:https://doi.org/

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

SPIN RSCI: 2787-5414
Scopus AuthorID: 6603382243
ResearcherID: U-5441-2019
ORCID: 0000-0003-4879-2687

Koroleva L.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Deshkina T.I.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Role of taxanes in adjuvant chemotherapy for breast cancer

Authors:

Bolotina L.V., Koroleva L.A., Deshkina T.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2012;1(1): 66‑69

Read: 1701 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Bolotina LV, Koroleva LA, Deshkina TI. Role of taxanes in adjuvant chemotherapy for breast cancer. P.A. Herzen Journal of Oncology. 2012;1(1):66‑69. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The paper gives the data of large randomized trials to study the role of taxanes in adjuvant chemotherapy regimens for stage I-III breast cancer. The findings are analyzed in relation to the clinical and molecular biological features of the tumor.

Keywords:

stage I-III breast cancer

adjuvant chemotherapy

taxanes

Authors:

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

SPIN RSCI: 2787-5414
Scopus AuthorID: 6603382243
ResearcherID: U-5441-2019
ORCID: 0000-0003-4879-2687

Koroleva L.A.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Deshkina T.I.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Close metadata

References:

Chissov V.I., Starinskii V.V., Petrova G.V., red. Zlokachestvennye novoobrazovaniya v Rossii v 2009 godu. M 2011; 138.
Bear H.D. et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006; 24: 2019-2027.
Burnell M.J. et al. Cyclophosphamide, epirubicin and fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by paclitaxel versus doxorubicin and cyclophosphamide followed by paclitaxel in node-positive or high-risk node-negative breast cancer. J Clin Oncol doi:10.1200/JCO.2009.22.1077 (2009).
Cognetti F. et al. Sequential epirubicin-docetaxel-CMF as adjuvant therapy for nodepositive early stage breast cancer: updated results of the TAXit216 randomized trial [abstract]. Ann Oncol 2008; 19: Suppl: a1820.
Del Mastro L. et al. Cyclophosphamide, epirubicin, and 5-fluorouracil versus epirubicin plus paclitaxel in node-positive early breast cancer patients: a randomized, phase III study of Gruppo Oncologico Nord Ovest-Mammella Intergruppo Group [abstract]. J Clin Oncol 2008; 26: Suppl: a516.
Dombernowsky P., Gehl J., Boesgaard M. et al. Treatment of metastatic breast cancer with paclitaxel and doxorubicin. Semin Oncol 1995; 22: 13-17.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
Ellis P. et al. Preliminary results of the UK Taxotere as Adjuvant Chemotherapy (TACT) Trial. In: Abstract #78 presented at the San Antonio Breast Cancer Symposium 2007.
Fan C. et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560-569.
Francis P. et al. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. J Natl Cancer Inst 2008; 100: 121-133.
Gianni L., Munzone E., Capri G. et al. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 1995; 13: 2688-2699.
Gianni L. et al. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer. J Clin Oncol 2009; 27: 2474-2481.
Goldstein L.J. et al. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 2008; 26: 4092-4099.
Henderson I.C. et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with nodepositive primary breast cancer. J Clin Oncol 2003; 21: 976-983.
Jacquemier J. et al. Identification of a basal-like subtype and comparative effect of epirubicinbased chemotherapy and sequential epirubicin followed by docetaxel chemotherapy in the PACS 01 reast cancer trial: 33 markers studied on tissue-microarrays (TMA) [abstract]. J Clin Oncol 2006; 24: Suppl: a509.
Joensuu H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
Jones S. et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 2009; 27: 1177-1183.
Mamounas E.P. et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005; 23: 3686-3696.
Martin M. et al. Adjuvant docetaxel for nodepositive breast cancer. N Engl J Med 2005; 352: 2302-2313.
Martin M. et al. Multicenter, randomized phase III study of adjuvant chemotherapy for high-risk, node-negative breast cancer comparing TAC with FAC: 5-year efficacy analysis of the GEICAM 9805 trial [abstract]. J Clin Oncol 2008; 26: Suppl: a542.
Martin M. et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 2008; 100: 805-814.
Michele De Laurentiis et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials. J Clin Oncol 2008; 26: 44-53.
Nitz U. et al. Interim results of Intergroup EC-Doc Trial: a randomized multicenter phase III trial comparing adjuvant CEF/CMF to EC-docetaxel in patients with 1-3 positive lymph nodes [abstract]. J Clin Oncol 2008; 26: Suppl: a515.
Philippe L. Bedard et al. Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 2010; 7: 22-36.
Roche H. et al. Sequential adjuvant epirubicinbased and docetaxel chemotherapy for nodepositive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006; 24: 5664-5671.